Progyny, Inc. $PGNY Shares Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. boosted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 99.5% during the second quarter, Holdings Channel.com reports. The institutional investor owned 162,397 shares of the company’s stock after buying an additional 81,004 shares during the period. Edgestream Partners L.P.’s holdings in Progyny were worth $3,573,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PGNY. Cetera Trust Company N.A increased its position in shares of Progyny by 303.1% during the second quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock worth $29,000 after acquiring an additional 985 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Progyny during the 1st quarter worth $44,000. Militia Capital Partners LP increased its holdings in Progyny by 100.0% during the 1st quarter. Militia Capital Partners LP now owns 2,000 shares of the company’s stock worth $45,000 after purchasing an additional 1,000 shares during the period. Brooklyn Investment Group raised its position in Progyny by 5,216.4% in the 1st quarter. Brooklyn Investment Group now owns 3,243 shares of the company’s stock valued at $72,000 after purchasing an additional 3,182 shares in the last quarter. Finally, AlphaQuest LLC boosted its stake in shares of Progyny by 57.9% in the 1st quarter. AlphaQuest LLC now owns 5,668 shares of the company’s stock valued at $127,000 after buying an additional 2,079 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PGNY. Canaccord Genuity Group upped their target price on shares of Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a research note on Monday, November 17th. Raymond James Financial set a $28.00 price objective on shares of Progyny in a report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Progyny in a research report on Wednesday, October 8th. JPMorgan Chase & Co. increased their target price on Progyny from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 price target (up from $26.00) on shares of Progyny in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.33.

Progyny Price Performance

Progyny stock opened at $24.55 on Thursday. The stock’s 50 day moving average price is $21.94 and its 200 day moving average price is $22.20. Progyny, Inc. has a 1-year low of $13.86 and a 1-year high of $27.51. The company has a market cap of $2.12 billion, a PE ratio of 38.97, a price-to-earnings-growth ratio of 1.96 and a beta of 0.97.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, November 6th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.06. The company had revenue of $313.35 million during the quarter, compared to the consensus estimate of $299.23 million. Progyny had a return on equity of 10.71% and a net margin of 4.46%.Progyny’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.11 earnings per share. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. On average, equities research analysts anticipate that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Insider Activity

In related news, CEO Peter Anevski acquired 79,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The shares were purchased at an average price of $24.29 per share, with a total value of $1,931,055.00. Following the completion of the acquisition, the chief executive officer owned 680,251 shares in the company, valued at approximately $16,523,296.79. This represents a 13.23% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Mark S. Livingston sold 21,303 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $25.50, for a total transaction of $543,226.50. Following the transaction, the chief financial officer owned 48,358 shares in the company, valued at $1,233,129. The trade was a 30.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 9.40% of the stock is owned by company insiders.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.